Bullish
Intellia Therapeutics (NTLA) is drawing attention after reporting positive Phase 3 data for its hereditary angioedema treatment, lonvoguran ziclumeran...
Bullish
Intellia Therapeutics (NASDAQ:NTLA) saw a 25% stock surge due to investor optimism over upcoming Phase 3 HAELO study data for its gene-editing treatme...
Intellia Therapeutics (NTLA) is drawing attention as it approaches the release of Phase 3 HAELO trial data for its gene editing therapy, lonvo-z, in h...